Composition

Each metered dose contains:
9 mcg Tiotropium Bromide (Monohydrate).

Indications

TIOTROPIUM Inhaler is indicated in the maintenance treatment of COPD.

Composition

Each actuation contains:

100/200/400 mcg Budesonide

6 mcg Formoterol (ex-valve).

Indications

FORMOTEROL/BUDESONIDE Inhaler is indicated in the regular treatment of asthma, where the use of a combination (long-acting, beta2-agonist and inhaled corticosteroid) has been found to be appropriate for instance:

Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting beta2 adrenoceptor agonists.

Or:

Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2 adrenoceptor agonists.

FORMOTEROL/BUDESONIDE Inhaler is also indicated as maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and emphysema.

Composition

Each actuation delivers:

125/250 mcg of Fluticasone Propionate

Indications

Fluticasone propionate given by inhalation offers prophylactic treatment for asthma.

Adults:

Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis.

Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.

Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids.

Children:

Any child who requires prophylactic medication, including patients not controlled on currently available prophylactic medication.

Composition

Each dose  contains:

120 mcg salbutamol sulphate

(equivalent to 100 mcg salbutamol),

50 mcg beclomethasone dipropionate.

Indications

Treatment of obstructive airway disease, especially intended for patients who require regular doses of both drugs.

Composition

Each actuation delivers:

25 mcg Salmeterol Xinafoate (ex- valve)+50 mcg of fluticasone propionate (ex-valve).

Indications

Salmeterol/ fluticasone is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short- acting β2 agonist or

- patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist .

Composition

Each actuation meters:

21 mcg of ipratropium bromide 120 mcg of salbutamol sulfate from the valve and delivers 18 mcg of ipratropium bromide and 103 mcg of salbutamol sulfate (equivalent to 90 mcg salbutamol base) from the mouthpiece.

Indications

IPRATAMOL is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.

Composition

Each actuation of the inhaler delivers:

67.8 mcg of levosalbutamol tartrate (equivalent to 51.6 mcg of levosalbutamol free base) from the valve and 59 mcg of levosalbutamol tartrate (equivalent to 45 mcg of levosalbutamol free base) from the actuator mouthpiece.

Indications

Bronchospasm:

LEVOSAL is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

Composition

Each actuation delivers :

25 mcg of salmeterol base (as salmeterol xinafoate) from the valve 

21 mcg of salmeterol base (as salmeterol xinafoate) from the actuator.

Indications

Asthma:

Salmeterol Inhalation Aerosol is indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of asthma and in the prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma, who require regular treatment with inhaled, short-acting beta2-agonists. It should not be used in patients whose asthma can be managed by occasional use of inhaled, short-acting beta2-agonists.

Salmeterol Inhalation Aerosol may be used alone or in combination with inhaled or systemic corticosteroid therapy.

Salmeterol Inhalation Aerosol is also indicated for prevention of exercise-induced bronchospasm in patients 12 years of age and older.

Chronic Obstructive Pulmonary Disease:

Salmeterol Inhalation Aerosol is indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).

Composition

Each metered dose (ex-valve) contains:

100 micrograms of Beclomethasone dipropionate and 6 micrograms of formoterol fumarate dihydrate.

Excipients: HFA 134a, anhydrous ethanol, Hcl. 

Indications

Beclolide plus is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting beta2-agonist or

- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2- agonists.

This product is indicated in adults.

Composition

each actuation delivers 80 / 160 mcg ciclesonide from the mouthpiece.

Indications

Treatment to control persistent asthma in adults and adolescents (12 years and older).

Composition

Each actuation contains :

6mcg Formoterol Fumarate (ex-valve) and 125/250mcg Fluticasone Propionate.

Excipients: HFA227a, absolute ethanol.

Indications

It is indicated in the regular treatment of asthma, where use of a combination (long-acting beta2-agonist and inhaled corticosteroid) has been found to be appropriate, and in patients with severe COPD.

Composition

Each actuation contains 120 mcg salbutamol sulfate (100mcg salbutamol base) (ex-valve) and 108 mcg salbutamol sulfate,(90mcg salbutamol base ) from the mouthpiece.

Indications

Allied salbutamol is indicated for the treatment of prevention of bronchospasm associated with reversible obstructive airway diseases and for the prevention of exercise induced bronchospasm in patients 4 years of age and older.

Composition

Each actuation contains 21 micrograms Ipratropium bromide (ex-valve) and 17 mcg of ipratropium bromide from the mouth piece.

Excipients:

 HFA134a, Absolute alcohol, anhydrous citric acid.

Indications

IPRASMA is a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Composition

AZMALIMIT 100: Each actuation delivers 100 mcg budesonide (ex-valve)

AZMALIMIT 200: Each actuation delivers 200 mcg budesonide (ex-valve)

The container contains 200 metered actuations

Excipients: alcohol, HFA 134a

Indications

AZMALIMIT is indicated for the maintenance treatment of asthma as Prophylactic therapy in adult and pediatric patients six years of age or older.  It is also indicated for patients requiring oral corticosteroid therapy  for  asthma . Many Of those patients may be able to reduce or eliminate their requirement for oral Corticosteroids   over   time.  Azmalimit   is not indicated for the relief of acute bronchospasm.

Composition

This canister contains 200 inhaler. Each inhaler contains 50/100/200 micrograms Beclomethasone dipropionate (ex-valve).

Indications

BECLOLIDE is indicated for the prophylactic management of mild, moderate, or severe asthma in adults or children: 

Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular basis 

Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone 

Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms

Composition

Each actuation contains: 9 mcg Tiotropium (as tiotropium bromide monohydrate) + 6mcg Formoterol fumarate dihydrate.

Excipients: HFA134a

Indications

Tio plus is indicated in the maintenance treatment of COPD (chronic obstructive pulmonary disease).